J. Deloumeaux, B. Bhakkan, and R. Eyraud, Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008-2013 from a population-based cancer registry, Cancer Causes Control, vol.28, pp.1265-73, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01688592

C. A. Haiman, G. K. Chen, and W. J. Blot, Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans

, PLoS Genet, vol.7, p.1001387, 2011.

E. Emeville, A. Giusti, X. Coumoul, J. Thomé, P. Blanchet et al., Associations of plasma concentrations of dichlorodiphenyldichloroethylene and polychlorinated biphenyls with prostate cancer: a case-control study in Guadeloupe (French West Indies), Environ Health Perspect, vol.123, pp.317-340, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01118553

S. Koutros, S. I. Berndt, and K. H. Barry, Genetic susceptibility loci, pesticide exposure and prostate cancer risk, PLoS One, vol.8, p.58195, 2013.

F. Khani, J. M. Mosquera, and K. Park, Evidence for molecular differences in prostate cancer between African American and Caucasian men, Clin Cancer Res, vol.20, pp.4925-4959, 2014.

A. Kamoun, G. Cancel-tassin, and G. Fromont, Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of a non-aggressive disease
URL : https://hal.archives-ouvertes.fr/hal-01863274

, Ann Oncol, vol.29, pp.1814-1835, 2018.

S. Ren, G. H. Wei, and D. Liu, Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression

, Eur Urol, vol.73, pp.322-361, 2018.

C. A. Doege, K. Inoue, and T. Yamashita, Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2, Nature, vol.488, pp.652-657, 2012.

M. L. Nickerson, S. Das, and K. M. Im, TET2 binds the androgen receptor and loss is associated with prostate cancer, Oncogene, vol.36, pp.2172-83, 2017.

J. Yang, C. Li, and A. Mudd, LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer, Biosci Biotechnol Biochem, vol.81, pp.2301-2307, 2017.

Y. M. Wu, M. Cie-slik, and R. J. Lonigro, Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer, Cell, vol.173, pp.1770-82, 2018.